---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-23-000051"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:45:15.420989+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharmaceuticals Reports Q3 2023 Revenue of $972M, Raises Full-Year Guidance

## Summary
- Xywav net product sales grew 30% year-over-year to $331.6M; total oxybate revenue annualizing at $1.9B
- Epidiolex net product sales up 9% to $213.7M; Rylaze up 43% to $104.9M
- Company raises 2023 total revenue guidance to $3.75-$3.875B and oncology guidance to $975M-$1.05B
- Plan to initiate zanidatamab rolling BLA submission this year for accelerated approval in 2L biliary tract cancers
- GAAP net income of $146.8M vs. loss of $19.6M in Q3 2022; non-GAAP adjusted net income $340.1M

## SEC filing metadata
- accession: 0001232524-23-000051
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000051/0001232524-23-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000051/jazz-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-23-000051
- JSON: https://secwatch.observer/filing/0001232524-23-000051.json
- Plain text: https://secwatch.observer/filing/0001232524-23-000051.txt

## Key facts
- Earnings Releases
  Jazz Pharmaceuticals plc updated its the quarter ended September 30, 2023 guidance (raised).
  - Period: the quarter ended September 30, 2023
  - Guidance: raised
  - Result: reported results
  source text: On November 8, 2023, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000051/0001232524-23-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.